The present invention relates to a 1-octene composition. The 1-octene composition according to the present invention is prepared by ethylene oligomerization and comprises a high content of 1-octene and monomers useful for copolymerization of 1-octene at the same time.

The present invention relates to a 1-octene composition. The 1-octene composition according to the present invention is prepared by ethylene oligomerization and comprises a high content of 1-octene and monomers useful for copolymerization of 1-octene at the same time.

The present invention relates to a 1-octene composition. The 1-octene composition according to the present invention is prepared by ethylene oligomerization and comprises a high content of 1-octene and monomers useful for copolymerization of 1-octene at the same time.

The present invention relates to a 1-octene composition. The 1-octene composition according to the present invention is prepared by ethylene oligomerization and comprises a high content of 1-octene and monomers useful for copolymerization of 1-octene at the same time.

The present invention relates to a 1-octene composition. The 1-octene composition according to the present invention is prepared by ethylene oligomerization and comprises a high content of 1-octene and monomers useful for copolymerization of 1-octene at the same time.

The present invention relates to a 1-octene composition. The 1-octene composition according to the present invention is prepared by ethylene oligomerization and comprises a high content of 1-octene and monomers useful for copolymerization of 1-octene at the same time.

Provided herein are Aminopurine compounds of Formula I: ##STR00001## or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R.sup.1, R.sup.2, and R.sup.3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.

Provided herein are Aminopurine compounds of Formula I: ##STR00001## or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R.sup.1, R.sup.2, and R.sup.3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.

Disclosed is a process for the conversion of acyclic C.sub.5 feedstock to a product comprising cyclic C.sub.5 compounds, such as, for example, cyclopentadiene, and catalyst compositions for use in such process. The process comprises the steps of contacting said feedstock and, optionally, hydrogen under acyclic C.sub.5 conversion conditions in the presence of a catalyst composition to form said product. The catalyst composition comprising a microporous crystalline aluminosilicate having a constraint index in the range of 3 to 12, a Group 10 metal, and, optionally, a Group 11 metal, in combination with a Group 1 alkali metal and/or a Group 2 alkaline earth metal.

Disclosed is a process for the conversion of acyclic C.sub.5 feedstock to a product comprising cyclic C.sub.5 compounds, such as, for example, cyclopentadiene, and catalyst compositions for use in such process. The process comprises the steps of contacting said feedstock and, optionally, hydrogen under acyclic C.sub.5 conversion conditions in the presence of a catalyst composition to form said product. The catalyst composition comprising a microporous crystalline aluminosilicate having a constraint index in the range of 3 to 12, a Group 10 metal, and, optionally, a Group 11 metal, in combination with a Group 1 alkali metal and/or a Group 2 alkaline earth metal.